




Shilpa

Pharma Lifesciences Limited

- 3 decades of presence with a mission of innovating for affordable healthcare.
- Integrated pharmaceutical company manufacturing Oncology & non-Oncology API's, Peptides, Polymers & Intermediates.
- 2 Manufacturing facilities and state of art R&D Sites.
- 17 Manufacturing Blocks.
- Global Regulatory Site Approvals-USFDA, EUGMP, PMDA, KFDA, EAEU etc.
- 44 USDMF's and 19 CEP's.
- 40 Oncology molecules in portfolio.
- Total 847 KL Capacity.
- 1500+ Employees.




API PRODUCT LIST

Oncology API's*

DMF Status

Axitinib	USDMF# 30104, EMEA/ASMF 01483
Azacitidine	USDMF# 27487, ASMF# EU/ ASMF /00265
Bendamustine HCl Monohydrate	USDMF# 25222, ASMF #551039
Bicalutamide	USDMF# 24690, ASMF # 551928
Bortezomib	USDMF# 24944, ASMF# EMEA/ASMF/01222
Busulfan	USDMF# 25491 R1-CEP 2011-339 - Rev 02,
Capecitabine	USDMF# 24689 R1-CEP 2014-332 - Rev 02,
Cabazitaxel	USDMF# 33087, ASMF # EU/ASMF/00475
Clofarabine	USDMF# 29806, ASMF # 552005
Cyclophosphamide	USDMF # 34066 R0-CEP 2020-083 - Rev 02,
Decitabine	USDMF# 27488, ASMF # 4769
Enzalutamide	USDMF# 30260
Erlotinib HCl	USDMF# 29124, ASMF # 4163
Gemcitabine HCl	USDMF # 31892 R0-CEP 2017-187 - Rev 01,
Ibrutinib	USDMF# 32122
Imatinib Mesylate	USDMF# 28349 R1-CEP 2016-121 - Rev 01,
Irinotecan HCl Trihydrate	USDMF# 23562 R1-CEP 2017-147-Rev 00,
Lenalidomide	USDMF# 33084
Lenvatinib Mesylate	USDMF# 33083
Letrozole	USDMF# 27489 R1-CEP 2013-321 - Rev 01,
Melphalan HCl	USDMF# 28930, ASMF No: 4755
Nilotinib	USDMF# 36289, EU/ASMF/00662/001
Oxaliplatin	USDMF# 2353, R1-CEP 2006-201-Rev 02,
Pemetrexed Disodium Hemipentahydrate	USDMF# 25102, R0-CEP 2022-087-Rev 00
Pomalidomide	USDMF# 32309, EU/ASMF/00670
Sorafenib Tosylate	DMF Filed, CEP 2022-056
Sunitinib Malate	USDMF# 33085, ASMF# EU/ASMF/00359/0001
Temozolomide	USDMF# 23479, R1-CEP 2016-277-Rev 00
Thalidomide	USDMF# 33088, ASMF#EU/ASMF/00374
Zoledronic Acid	USDMF# 25905, R0-CEP 2021-269-Rev 00
Abiraterone Acetate	DMF Available
Dasatinib	DMF Available
Pazopanib Hcl	DMF Available
Afatinib Dimaleate	Tech. Pack available
Carmustine	Tech. Pack available
Nintedanib	Tech. Pack available
Palbociclib	Tech. Pack available



Non-Oncology API's*

DMF Status

Ambroxol HCl	R1-CEP 2004-201 - Rev 05
Amifampridine	ASMF # 4755
Citicoline	DMF Available
Dimethyl Fumarate	USD MF# 29655
Fingolimod HCl	USD MF# 28162 R0-CEP 2019-145 - Rev 01, DMF Available, R0-CEP 2021-268-Rev 00
Glycopyrronium Bromide	USD MF # 36235, CEP 2022-475
Nifedipine	DMF Available CEP 2022-458
Oxcarbazepine	USD MF # 36236
Phenylephrine HCl	USD MF# 30952 R1-CEP 2016-242 - Rev 00, USD MF # 35038, ASMF: EU/ASMF/00355
Pirfenidone	USD MF # 33850
Prucalopride Succinate	APIMF – 391 (WHO)
Tenofovir Alafenamide	USD MF# 32172
Tenofovir Disoproxil Fumarate	USD MF# 33086 R0-CEP 2018-048 - Rev 01, DMF Available, CEP 2022-275
Teriflunomide	USD MF # 35037, ASMF# EU/ASMF/00489
Tranexamic Acid	DMF available
Ursodeoxycholic Acid	Tech Pack available
Varenicline Tartrate	Tech Pack available
Montelukast	
Eltrombopag Olamine	
Selexipag	

Peptides


DMF Status

Desmopressin	Tech Pack available
Liraglutide	Tech Pack available
Octreotide	Tech Pack available
Semaglutide	Tech Pack available
Leuprolide	Developed in R&D, Validation planned
Vasopressin	Developed in R&D, Validation planned

Products Under Development

Docetaxel
Methotrexate
Cytarabine
Levocarnitine
Olaparib
Regarofinib
Tofacitinib Citrate

*Products covered by valid patents in any country are not offered or supplied to those countries.





Unit-1-Deosugur, Raichur, India
API Onco & non-Onco Facility. 7 API blocks with 325 KL capacity




Unit-2-Chicksugur, Raichur, India
API Onco & non-Onco Facility. 10 API blocks with 522 KL capacity



Shilpa Pharma Lifesciences Limited

CORPORATE OFFICE:

Shilpa House, Hyderabad Road, Raichur – 584 135 Karnataka, India



MARKETING OFFICE:

Office No. 1, "A" Wing, Ground Floor, Trade Star Building, J. B. Nagar,
Andheri-Kurla Road, Andheri East, Mumbai - 400059 Maharashtra, India